Literature DB >> 15315795

Impact of beta globin gene mutations on the clinical phenotype of beta thalassemia in India.

Roshan Colah1, Anita Nadkarni, Ajit Gorakshakar, Supriya Phanasgaonkar, Reema Surve, P G Subramaniam, Nagnath Bondge, Kamala Pujari, Kanjaksha Ghosh, Dipika Mohanty.   

Abstract

The beta thalassemias are one of the commonest group of autosomal recessive disorders in India. Although majority of patients are severe and transfusion-dependent, about 10-15% of cases have a milder phenotype. We evaluated the role of beta gene mutations in modulating the clinical presentation of 342 beta thalassemia patients which included 278 severe thalassemia major (TM) and 64 thalassemia intermedia (TI) cases (severe TI: 27; mild TI: 37) from this region. Thirteen beta thalassemia mutations were characterized by reverse dot blot hybridization or amplification refractory mutation system (ARMS); denaturing gradient gel electrophoresis (DGGE) analysis and DNA sequencing helped to characterize the remaining nine mutations. Majority of the patients in the thalassemia major and thalassemia intermedia groups had severe beta+ or beta0 mutations. IVS 1-5 (G-->C) was the commonest mutation in the three groups. The six severe and common Indian mutations [(IVS 1-5 (G-->C), 619 bp deletion, IVS 1-1 (G-->T), codons 8/9 (+G), codon 15 (G-->A), codons 41/42 (-CTTT)] accounted for 92.0% of molecular lesions in the thalassemia major group, 86.8% in the severe TI group, and 72.9% in the mild TI group. IVS 1-1 (G-->T) and codon 30 (G-->C) were significantly more common in thalassemia intermedia cases. The mild capsite +1 (A-->C) mutation was present in both severe and mild cases. Three other mild beta+ mutations, poly A (T-->C), -28 (A-->G), and -88 (C-->T), were seen only in the thalassemia intermedia cases. These four mild mutations in combination with other severe beta+ or beta0 mutations resulted in a very variable clinical presentation. This study reveals that, in majority of Indian patients, the beta genotype cannot predict the phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315795     DOI: 10.1016/j.bcmd.2004.05.002

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  5 in total

1.  Haematology research in India: past, present and future.

Authors:  Kanjaksha Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2011-05-08       Impact factor: 0.900

2.  Using 5'-PTMs to repair mutant beta-globin transcripts.

Authors:  Monique N Kierlin-Duncan; Bruce A Sullenger
Journal:  RNA       Date:  2007-06-07       Impact factor: 4.942

3.  Changes in lncRNAs and related genes in β-thalassemia minor and β-thalassemia major.

Authors:  Jing Ma; Fei Liu; Xin Du; Duan Ma; Likuan Xiong
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

4.  Next-generation sequencing improves thalassemia carrier screening among premarital adults in a high prevalence population: the Dai nationality, China.

Authors:  Jing He; Wenhui Song; Jinlong Yang; Sen Lu; Yuan Yuan; Junfu Guo; Jie Zhang; Kai Ye; Fan Yang; Fangfang Long; Zhiyu Peng; Haijing Yu; Le Cheng; Baosheng Zhu
Journal:  Genet Med       Date:  2017-01-26       Impact factor: 8.822

5.  Significance of genetic modifiers of hemoglobinopathies leading towards precision medicine.

Authors:  Priya Hariharan; Manju Gorivale; Pratibha Sawant; Pallavi Mehta; Anita Nadkarni
Journal:  Sci Rep       Date:  2021-10-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.